BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew Sells 25,000 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 25,000 shares of the firm’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $21.17, for a total value of $529,250.00. Following the completion of the transaction, the executive vice president now directly owns 302,046 shares in the company, valued at $6,394,313.82. This trade represents a 7.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

BioLife Solutions Trading Up 9.6 %

Shares of BLFS opened at $22.44 on Wednesday. BioLife Solutions, Inc. has a 1 year low of $11.91 and a 1 year high of $28.88. The company has a 50 day simple moving average of $23.92 and a two-hundred day simple moving average of $22.87. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The firm has a market cap of $1.04 billion, a P/E ratio of -21.17 and a beta of 1.88.

Hedge Funds Weigh In On BioLife Solutions

Several institutional investors have recently bought and sold shares of BLFS. Mark Sheptoff Financial Planning LLC purchased a new stake in BioLife Solutions in the 3rd quarter worth $28,000. 1620 Investment Advisors Inc. purchased a new stake in shares of BioLife Solutions in the second quarter worth about $35,000. Isthmus Partners LLC lifted its position in shares of BioLife Solutions by 34.4% in the second quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 42,265 shares in the last quarter. Quest Partners LLC bought a new position in BioLife Solutions during the third quarter valued at approximately $57,000. Finally, GAMMA Investing LLC grew its holdings in BioLife Solutions by 29.4% during the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after buying an additional 748 shares in the last quarter. 93.24% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Craig Hallum increased their target price on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. TD Cowen upped their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. HC Wainwright decreased their price objective on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Monday. Finally, Northland Securities lifted their target price on shares of BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.50.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.